|
|
Blood, 15 December 2003, Vol. 102, No. 13, pp. 4464-4471.
Prepublished online as a Blood First Edition Paper on August 21, 2003; DOI 10.1182/blood-2003-03-0974.
 Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
Differential effects of treatment with a small-molecule VLA-4 antagonist before and after onset of relapsing EAE
Bradley E. Theien,
Carol L. Vanderlugt,
Cheryl Nickerson-Nutter,
Mark Cornebise,
Daniel M. Scott,
Stuart J. Perper,
Eric T. Whalley, and
Stephen D. Miller
From the Department of Microbiology-Immunology and the Interdepartmental Immunobiology Center, Northwestern University Medical School, Chicago, IL; and Biogen Inc, Cambridge, MA.
Interaction of very late antigen-4 (VLA-4) with its ligand vascular cell adhesion molecule-1 (VCAM-1) is required for central nervous system (CNS) migration of encephalitogenic T cells in relapsing experimental autoimmune encephalomyelitis (R-EAE). Anti-VLA-4 monoclonal antibody (mAb) treatment prior to EAE onset inhibits disease induction; however, treatment initiated after the appearance of clinical symptoms increases relapse rates, augments Th1 responses, and enhances epitope spreading perhaps due to the activation of costimulatory signals. To negate the potential costimulatory activity of intact anti-VLA-4, we examined the ability of BIO 5192, a small-molecule VLA-4 antagonist, to regulate active proteolipid protein 139-151 (PLP139-151)-induced R-EAE. BIO 5192 administered one week after peptide priming (ie, before clinical disease onset) delayed the clinical disease onset but led to severe disease exacerbation upon treatment removal. BIO 5192 treatment initiated during disease remission moderately enhanced clinical disease while mice were on treatment and also resulted in posttreatment exacerbation. Interestingly, BIO 5192 treatment begun at the peak of acute disease accelerated entrance into disease remission and inhibited relapses, but treatment removal again exacerbated disease. Enhanced disease was caused by the release of encephalitogenic cells from the periphery and the rapid accumulation of T cells in the CNS. Collectively, these results further demonstrate the complexity of VLA-4/VCAM interactions, particularly in a relapsing-remitting autoimmune disease. (Blood. 2003;102:4464-4471)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Agius, K. E. Lacy, M. Vukmanovic-Stejic, A. L. Jagger, A.-P. Papageorgiou, S. Hall, J. R. Reed, S. J. Curnow, J. Fuentes-Duculan, C. D. Buckley, et al.
Decreased TNF-{alpha} synthesis by macrophages restricts cutaneous immunosurveillance by memory CD4+ T cells during aging
J. Exp. Med.,
August 31, 2009;
206(9):
1929 - 1940.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. N. Abboud
Another nail in the AML coffin
Blood,
June 11, 2009;
113(24):
6045 - 6046.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Kivisakk, B. C. Healy, V. Viglietta, F. J. Quintana, M. A. Hootstein, H. L. Weiner, and S. J. Khoury
Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells
Neurology,
June 2, 2009;
72(22):
1922 - 1930.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Meads, L. A. Hazlehurst, and W. S. Dalton
The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance
Clin. Cancer Res.,
May 1, 2008;
14(9):
2519 - 2526.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Fox and L. Kappos
Is natalizumab overshooting its rebound?
Neurology,
March 25, 2008;
70(13_Part_2):
1073 - 1074.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Kerfoot, M. U. Norman, B. M. Lapointe, C. S. Bonder, L. Zbytnuik, and P. Kubes
Reevaluation of P-Selectin and {alpha}4 Integrin as Targets for the Treatment of Experimental Autoimmune Encephalomyelitis
J. Immunol.,
May 15, 2006;
176(10):
6225 - 6234.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Glasner, H. Blum, V. Wehner, H. U. Stilz, J. D. Humphries, G. P. Curley, A. P. Mould, M. J. Humphries, R. Hallmann, M. Rollinghoff, et al.
A Small Molecule {alpha}4{beta}1 Antagonist Prevents Development of Murine Lyme Arthritis without Affecting Protective Immunity
J. Immunol.,
October 1, 2005;
175(7):
4724 - 4734.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Pepinsky, W.-C. Lee, M. Cornebise, A. Gill, K. Wortham, L. L. Chen, D. R. Leone, K. Giza, B. M. Dolinski, S. Perper, et al.
Design, Synthesis, and Analysis of a Polyethelene Glycol-Modified (PEGylated) Small Molecule Inhibitor of Integrin {alpha}4{beta}1 with Improved Pharmaceutical Properties
J. Pharmacol. Exp. Ther.,
February 1, 2005;
312(2):
742 - 750.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Deloire, T. Touil, B. Brochet, V. Dousset, J.-M. Caille, and K. G Petry
Macrophage brain infiltration in experimental autoimmune encephalomyelitis is not completely compromised by suppressed T-cell invasion: in vivo magnetic resonance imaging illustration in effective anti-VLA-4 antibody treatment
Multiple Sclerosis,
October 1, 2004;
10(5):
540 - 548.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Mittelbrunn, A. Molina, M. M. Escribese, M. Yanez-Mo, E. Escudero, A. Ursa, R. Tejedor, F. Mampaso, and F. Sanchez-Madrid
VLA-4 integrin concentrates at the peripheral supramolecular activation complex of the immune synapse and drives T helper 1 responses
PNAS,
July 27, 2004;
101(30):
11058 - 11063.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
